These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38919512)

  • 21. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.
    Quesada PR; Esteban LL; García JR; Sánchez RV; García TM; Alonso-Vega GG; Ferrández JS
    Int J Clin Pharm; 2015 Oct; 37(5):865-72. PubMed ID: 26008219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium.
    Byonanebye DM; Polizzotto MN; Neesgaard B; Sarcletti M; Matulionyte R; Braun DL; Castagna A; de Wit S; Wit F; Fontas E; Vehreschild JJ; Vesterbacka J; Greenberg L; Hatleberg C; Garges H; Gallant J; Volny Anne A; Öllinger A; Mozer-Lisewska I; Surial B; Spagnuolo V; Necsoi C; van der Valk M; Mocroft A; Law M; Ryom L; Petoumenos K;
    HIV Med; 2022 Sep; 23(8):895-910. PubMed ID: 35233903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
    Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.
    Mocroft A; Lundgren JD; Ross M; Fux CA; Reiss P; Moranne O; Morlat P; Monforte Ad; Kirk O; Ryom L;
    Lancet HIV; 2016 Jan; 3(1):e23-32. PubMed ID: 26762990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of antiretrovirals in HIV-infected patients with cancer.
    Torres HA; Rallapalli V; Saxena A; Granwehr BP; Viola GM; Ariza-Heredia E; Adachi JA; Chemaly RF; Marfatia R; Jiang Y; Mahale P; Kyvernitakis A; Fanale MA; Mulanovich V
    Clin Microbiol Infect; 2014 Oct; 20(10):O672-9. PubMed ID: 24529214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort.
    Di Biagio A; Nicolini LA; Lorenzini P; Puoti M; Antinori A; Cozzi-Lepri A; Gori A; Vecchiet J; Mussini C; Andreoni M; Viscoli C; d'Arminio Monforte A; For The Icona Foundation Study Group
    HIV Clin Trials; 2014; 15(4):151-60. PubMed ID: 25143024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012.
    Morlat P; Vivot A; Vandenhende MA; Dauchy FA; Asselineau J; Déti E; Gerard Y; Lazaro E; Duffau P; Neau D; Bonnet F; Chêne G;
    PLoS One; 2013; 8(6):e66223. PubMed ID: 23776637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Antiretroviral Drugs on Fracture Risk in HIV-Infected Individuals: A Case-Control Study Nested Within the French Hospital Database on HIV (FHDH-ANRS CO4).
    Costagliola D; Potard V; Lang S; Abgrall S; Duvivier C; Fischer H; Joly V; Lacombe JM; Valantin MA; Mary-Krause M; Rozenberg S
    J Acquir Immune Defic Syndr; 2019 Feb; 80(2):214-223. PubMed ID: 30422911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
    Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
    Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention.
    Yap PK; Loo Xin GL; Tan YY; Chellian J; Gupta G; Liew YK; Collet T; Dua K; Chellappan DK
    J Pharm Pharmacol; 2019 Sep; 71(9):1339-1352. PubMed ID: 31144296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review.
    Toledo T; Castro T; Oliveira VG; Veloso VG; Grinsztejn B; Cardoso SW; Torres TS; Estrela R
    Clin Pharmacokinet; 2023 Sep; 62(9):1219-1230. PubMed ID: 37561283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies.
    Wandeler G; Mauron E; Atkinson A; Dufour JF; Kraus D; Reiss P; Peters L; Dabis F; Fehr J; Bernasconi E; van der Valk M; Smit C; Gjærde LK; Rockstroh J; Neau D; Bonnet F; Rauch A;
    J Hepatol; 2019 Aug; 71(2):274-280. PubMed ID: 30965070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of darunavir in HIV-1-infected individuals in routine clinical practice from 2012 to 2016 in France.
    Potard V; Canestri A; Gallien S; Costagliola D;
    J Antimicrob Chemother; 2019 Nov; 74(11):3305-3314. PubMed ID: 31384941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rethinking the "pre" in pre-therapy counseling: no benefit of additional visits prior to therapy on adherence or viremia in Ugandans initiating ARVs.
    Siedner MJ; Lankowski A; Haberer JE; Kembabazi A; Emenyonu N; Tsai AC; Muzoora C; Geng E; Martin JN; Bangsberg DR
    PLoS One; 2012; 7(6):e39894. PubMed ID: 22761924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study.
    de Boissieu P; Dramé M; Raffi F; Cabie A; Poizot-Martin I; Cotte L; Garraffo R; Delobel P; Huleux T; Rey D; Bani-Sadr F;
    Medicine (Baltimore); 2016 Sep; 95(37):e4890. PubMed ID: 27631261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal Dysfunction during Tenofovir Use in a Regional Cohort of HIV-Infected Individuals in the Asia-Pacific.
    Tanuma J; Jiamsakul A; Makane A; Avihingsanon A; Ng OT; Kiertiburanakul S; Chaiwarith R; Kumarasamy N; Nguyen KV; Pham TT; Lee MP; Ditangco R; Merati TP; Choi JY; Wong WW; Kamarulzaman A; Yunihastuti E; Sim BL; Ratanasuwan W; Kantipong P; Zhang F; Mustafa M; Saphonn V; Pujari S; Sohn AH;
    PLoS One; 2016; 11(8):e0161562. PubMed ID: 27560968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.
    Pedrol E; Caro-Murillo AM; Castaño MA; Riera M; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Pulido F; Romero-Palacios A; Aguirrebengoa K; Vera F; Ferrer P; Blanco Ramos JR
    HIV Clin Trials; 2015; 16(1):43-8. PubMed ID: 25777189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice.
    Ranzenigo M; Gianotti N; Galli L; Poli A; Mastrangelo A; Bruzzesi E; Chiurlo M; Nozza S; Bossolasco S; Spagnuolo V; Mancusi D; Termini R; Carini E; Lazzarin A; Castagna A
    Drug Des Devel Ther; 2022; 16():1975-1982. PubMed ID: 35783200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
    Avihingsanon A; Hughes MD; Salata R; Godfrey C; McCarthy C; Mugyenyi P; Hogg E; Gross R; Cardoso SW; Bukuru A; Makanga M; Badal-Aesen S; Mave V; Ndege BW; Fontain SN; Samaneka W; Secours R; Van Schalkwyk M; Mngqibisa R; Mohapi L; Valencia J; Sugandhavesa P; Montalban E; Munyanga C; Chagomerana M; Santos BR; Kumarasamy N; Kanyama C; Schooley RT; Mellors JW; Wallis CL; Collier AC; Grinsztejn B;
    J Int AIDS Soc; 2022 Jun; 25(6):e25905. PubMed ID: 36039892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.